PERPUSTAKAAN DIGITAL
POLITEKNIK KESEHATAN KEMENKES SURABAYA




STATISTIK

Total Klik:3122609
Pengunjung:66231
Klik Dalam 24jam:1376
Pengunjung Dalam 24jam:395
Yang Sedang Online:6


RSS
 
PENELUSURAN INFORMASI

Masukkan kata pencarian pada kotak diatas
 
 Article  (339)
 Books (94)
 Journal (212)
 Images (1)
 Multimedia (1)
 Proceeding (52)
 Publication (197)
 Studi Report (4022)


 

POLTEKKESSBY » Journal » Jurusan Analis Kesehatan
di-posting oleh noeramelia@poltekkesdepkes-sby.ac.id pada 2021-09-07 09:45:48  •  36 klik          Permohonan Koleksi

Diffuse large B-cell lymphoma with primary treatment failure: Ultra-high risk features and benchmarking for experimental therapies

American Journal of HematologyVolume 92, Issue 2 e24615 p. 161-170

disusun oleh Luciano J. Costa,Kami Maddocks,Narendranath Epperla

Subyekdiffuse large B-cell lymphoma (DLBCL)
Kata Kunci diffuse large B-cell lymphoma (DLBCL)
Tanggal tercipta2020-01-05
Jenis(Tipe)Journal
Bentuk(Format)Pdf link
BahasaInggris
Pengenal(Identifier)POLTEKKESSBY-Journal-12JRLi2017001
No Koleksi12JRLi2017001
No Klasifikasi616. 9 J
Link Publikasihttps://onlinelibrary.wiley.com/doi/10.1002/ajh.24615


Sumber :
Wiley Online Library

Cakupan (Coverage) :
Bidang Kesehatan


[ ANOTASI / ABSTRAK ]

Abstract The outcomes of patients with DLBCL and primary treatment failure (PTF) in the rituximab era are unclear. We analyzed 331 patients with PTF, defined as primary progression while on upfront chemoimmunotherapy (PP), residual disease at the end of upfront therapy (RD) or relapse < 6 months from end of therapy (early relapse; ER). Median age was 58 years and response to salvage was 41.7%. Two-year OS was 18.5% in PP, 30.6% in RD and 45.5% in ER. The presence of PP, intermediate-high/high NCCN-IPI at time of PTF or MYC translocation predicted 2-year OS of 13.6% constituting ultra-high risk (UHR) features. Among the 132 patients who underwent autologous hematopoietic cell transplantation, 2-year OS was 74.3%, 59.6% and 10.7% for patients with 0,1 and 2–3 UHR features respectively. Patients with PTF and UHR features should be prioritized for clinical trials with newer agents and innovative cellular therapy.



[ DESKRIPSI LAIN ]

 Download File Penyerta (khusus anggota terdaftar)

...Tidak ada file penyerta...
 Download File Penyerta (Bebas Unduh)

...Tidak ada file penyerta...